0.0210USD+5.00%Mkt Cap: 947360 USDP/E: 0.00Last update: 2026-05-22
CERo Therapeutics Holdings, Inc., an immunotherapy company, engages in the development of engineered T cell therapeutics for the treatment of cancer. The company's lead development candidate is CER-1236, an autologous T …
Industry Peers
Biotechnologyloading…
Indicators:|
Key Statistics
Company
Market Cap947.36K USD
Enterprise Value7.86M USD
Revenue (TTM)—
Gross Profit-605.42K USD
Net Income (TTM)-19.92M USD
Revenue/Share—
Last Price0.0210 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees8
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)0.00
P/E (Forward)-0.01
PEG—
EV/EBITDA-0.41
EV/Revenue—
P/S—
P/B-0.03
EPS (TTM)9.04
EPS (Forward)-3.26
52W Range
0.01800% of range26.99
52W High26.99 USD
52W Low0.0180 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE365.75%
ROA-547.09%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-16.08M USD
CapEx (TTM)—
FCF Margin—
FCF Yield-542.35%
Net Debt-259.14K USD
Net Debt/EBITDA0.01
Balance Sheet
Debt/Equity-0.13
Current Ratio0.14
Quick Ratio0.08
Book Value/Sh-0.6020 USD
Cash/Share0.0190 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:20
Split DateJun 13, 2025
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.45.11M
Float43.14M
Insiders4.13%
Institutions0.14%
Short Interest
Short Ratio0.8d
Short % Float10.50%
Short % Out.10.34%
Shares Short192.89K
Short (prev mo.)106.18K
Technical
SMA 500.0312 (-32.8%)
SMA 2001.699 (-98.8%)
Beta—
S&P 52W Chg28.31%
Avg Vol (30d)639.99K
Avg Vol (10d)615.04K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—